Who We Are
Healthcare Expertise +
relentless focus +
a balanced approach =
an algorithm for clinical
change that matters.
GI Windows
WHAT IF?
Just suppose…
It always starts with an idea to improve something. With a lot of determination, an idea can turn into an invention, and then evolve into an intervention, or even begin its own ecosystem…forever changing the future of the way something is done.
​
But the steps to prove out an invention and develop it into clinical practice takes expertise, determination and vision. And that’s what GI Windows is all about.
​
GI Windows is developing the first fundamental breakthrough in surgical anastomotic technology. This technology will allow less invasive surgery and offer the capability of developing more procedures new to the world. The vision of the GI Windows team is to develop and commercialize a less invasive intervention to help thwart the worldwide epidemic of Obesity & Type 2 diabetes.
​
The team is made up of experienced individuals who have successfully demonstrated their cross-functional expertise to bring meaningful medical technologies to market. They are committed to innovation that helps improve the way diagnostic and interventional procedures impact the essential balance between both patients and the healthcare system.
​
​
​
​
vision.
Civil & Commercial
Trust, Wills & Probate
OUR DISRUPTIVE IMPACT TO HEALTHCARE
Less invasive delivery, new procedures,
reduced complications and ease of use.
Commitment.
Expertise.
“Technology to reshape the future of surgical anastomotic procedures and bring tangible benefits to patients and the healthcare system.”
“Type 2 diabetes is an enormous clinical issue and we need to be aggressively thinking about innovation to impede its progress; put up a defense against it.”
Christopher Thompson, MD Associate Professor of Medicine Harvard
“New technology and the cost to implement
and maintain it in a meaningful way can
be a precarious balance; advancements
need to ensure a balance with clinical,
operational and economic elements.”
“Type 2 diabetes is an enormous clinical issue and we need to be aggressively thinking about innovation to impede its progress; put up a defense against it.”
INVESTORS
Financial Partners
Corporate Partners
